Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
Nanotheranostics|October 27, 2017
Accumulation of <sup>111</sup>In-Labelled EGF-Au-PEG Nanoparticles in EGFR-Positive Tumours is Enhanced by Coadministration of Targeting LigandLei Song, Sarah Able, Errin Johnson, et al.Molecular Cancer Therapeutics|August 22, 2013
Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AXBart Cornelissen, Andrew Waller, Sarah Able, et al.Nature Chemistry|February 11, 2022
Tricyclic cell-penetrating peptides for efficient delivery of functional antibodies into cancer cellsOle Tietz, Fernando Cortezon-Tamarit, Rod Chalk, et al.Journal of Labelled Compounds & Radiopharmaceuticals|September 6, 2016
Synthesis and evaluation of an <sup>18</sup> F-labeled derivative of F3 for targeting surface-expressed nucleolin in cancer and tumor endothelial cellsPhoebe Y H Lam, Christopher R T Hillyar, Sarah Able, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 1, 2018
Targeting Micrometastases: The Effect of Heterogeneous Radionuclide Distribution on Tumor Control ProbabilityNadia Falzone, Boon Quan Lee, Sarah Able, et al.Biomaterials|November 23, 2012
Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumorsBart Cornelissen, Sarah Able, Veerle Kersemans, et al.EJNMMI Research|June 1, 2017
Monitoring response to anti-angiogenic mTOR inhibitor therapy in vivo using <sup>111</sup>In-bevacizumabNeel Patel, Sarah Able, Danny Allen, et al.Physics in Medicine and Biology|May 23, 2019
Radiosensitivity of colorectal cancer to <sup>90</sup>Y and the radiobiological implications for radioembolisation therapyBoon Q Lee, Elliot M Abbott, Sarah Able, et al.Cancer & Metabolism|October 15, 2021
3-Bromopyruvate-mediated MCT1-dependent metabolic perturbation sensitizes triple negative breast cancer cells to ionizing radiationIrini Skaripa-Koukelli, David Hauton, John Walsby-Tickle, et al.Nanoscale|May 30, 2018
<sup>111</sup>In-labelled polymeric nanoparticles incorporating a ruthenium-based radiosensitizer for EGFR-targeted combination therapy in oesophageal cancer cellsMartin R Gill, Jyothi U Menon, Paul J Jarman, et al.Pageof 2